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Abstract 
The Relationship of Chlamydia antigen, AD-like pathology, and Inflammation in 
the brains of intranasally infected BALB/c mice 
Brittany L. Kane 
MS in Biomedical Sciences August 2015 
Depmiment of Pathology, Microbiology, Immunology and Forensic Medicine 
Philadelphia College of Osteopathic Medicine, Philadelphia, P A 
C. Scott Little, Ph.D. Thesis Advisor 
Alzheimer's' Disease (AD) is a progressive neurodegenerative disease that affects 
millions of elderly individuals in the westem world. There are two f01ms of AD, sporadic 
late-onset AD and Familial AD. The neuropathy seen in both cases of AD is the same; 
neurofibrillary tangles (NFTs) that are composed of modified tau protein, and nemitic 
senile plaques (NSPs) composed of deposited beta amyloid peptide. The objective of this 
study is to continue to investigate the role of infection as a possible risk factor for 
sporadic AD. Previous mouse models using Chlamydia pneumoniae demonstrated that 
intranasal inoculation with this organism induced AD-like pathology in mouse brain 
tissue { {17 Little,C.S.( 1) 2004;} }. Previous studies examined non-transgenic BALB/c 
mice that were intranasally inoculated with an in vivo passaged isolate of C. muridarum 
(C small Weiss) and a stock isolate of C. muridarwn (mouse pneumonitis Weiss), a 
mouse adapted respiratory isolate of C. trachoma tis. The presence of C. m.uridarum 
iii 
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antigen as well as deposited beta amyloid was established at the 60-day time point. The 
goal of this study was to detetmine whether astrocyte activation would be identified 
within brain tissue previously verified with infection of C. muridarum and deposited beta 
amyloid. Based on previously observed AD-like pathology, it was hypothesized that 
astrocytes will respond to infection and deposited beta amyloid and become activated. At 
the 2 month time point, Semiquantitative, immunohistochemical and microscopic 
analysis revealed great variability in glial cell specific labeling in mice intrasnasally 
inoculated with either isolate of C. muridarum. Analysis of the stock isolate of C. 
muridarum revealed an approximate 3-fold increase between the titer negative group and 
the titer positive 1:20480 expetimental group. Analysis of the in vivo passaged isolate 
displayed less than a 10% difference in total glial cell number between the titer negative 
and the titer positive 1:10240 experimental group. These data indicate that intranasal 
infection with C. muridarum induces glial cell activation in the brains ofBALB/c mice. 
However these data suggest that the degree of activation is dependent on the isolate of C. 
muridarum introduced. The initial hypothesis proposed that glial cell burden would 
increase in response to chlamydia infection and amyloid pathology. However, an inverse 
con-elation between glial cell count and amyloid deposit burden was noted in both 
isolates of C. muridarum, although there was a considerably greater inverse con·elation 
between glial cell count and amyloid burden in the mouse pneumonitis Weiss stock 
group. In accordance with the initial hypothesis, as chlamydia antigen burden increased, 
glial cell counts also increased in the C small Weiss group. However, the relationship of 
glial cells and chlamydia antigen burden differed from the initial hypothesis for the 
mouse pneumonitis Weiss group. As chlamydia antigen burden increased, glial cell 
iv 
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counts decreased. These data suggest that the in vivo passaged C small Weiss isolate is 
more virulent than the stock passaged mouse pneumonitis Weiss isolate of C. muridarum. 
v 
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1. Introduction 
1.1 Alzheimer's Disease Prevalence and Significance 
Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of elderly 
individuals in the western world (1). The prevalence of this disease increases with age 
and is believed to affect between 24% and 33% of people that are over the age of85 (2). 
According to cunent estimates, there are 24 million cases of AD worldwide and it 
accounts for 50-60% of all cases of dementia. 
1.2 Signs and Symptoms of AD 
1 
Alzheimer's Disease is characterized by a progressive loss of cognitive function 
caused by degeneration in the medial temporal lobe, which eventually spreads through 
the limbic system to the association and primary cortices (3). Neurodegeneration 
associated with AD is believed to begin 20-30 years before clinical onset, and is 
classified as the preclinical phase. As first symptoms appear, the condition is often 
described as mild cognitive impaitment (MCI) (2) . The first areas affected are the 
regions involved in the processing and storage of new memory, the hippocampus and the 
entorhinal cortex (4). Individuals at this stage experience more memory problems than 
normal for people their age, yet the impairment with MCI is not as severe as that seen in 
AD (5). A decline in cognitive processes such as word finding, visual/spatial issues, and 
problems with judgment or reasoning, are symptoms characteristic ofMCI progressing to 
mild AD. Mild AD is associated with memory loss and a decline in other cognitive 
abilities as well as mood and personality changes, repeating questions, and taking longer 
to complete a daily task (6). As the disease progresses to moderate AD, damage occurs 
in areas of the brain responsible for language, reasoning, sensory processing and 
conscious thought. At this stage, memory loss worsens and patients may have difficulty 
leaming new things and recognizing fi·iends and family. As the disease progresses to 
severe AD, plaques and tangles have spread tlu·oughout the brain. People at tllis stage 
cannot c01mnunicate and are entirely dependent on others for their care (6). 
1.3 Alzheimer's Disease Pathogenesis and Pathology 
There are two fonns of AD, sporadic late-onset AD and Familial AD. The 
neuropathology seen in both cases of AD is the same; neurofibrillary tangles (NFTs) that 
are composed of modified tau protein, and neuritic senile plaques (NSPs) composed of 
deposited beta amyloid peptide (7). Beta amyloid deposition is believed to play a role in 
the neuronal degeneration seen in AD. 
Familial AD is caused by genetic mutations that lead to pathology (1) . The first 
mutation identified to cause the familial form of the disease is the amyloid precursor 
protein (APP) gene on chromosome 21. The protein is digested by proteases near the 
carboxyl-tenninus leading to the production of beta amyloid. Mutation on the APP gene 
is associated with increased deposition of beta amyloid. Genes encoding for 
transmembrane proteins presenilin-1 (PS-1) and presenilin-2 (PS-2) are also involved in 
the development of the familial f01m of AD. Mutations in these genes also lead to 
increased beta amyloid deposition and are responsible for most of the familial cases (2, 
8). However, the familial fonn of this disease is rare. 
2 
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Sporadic AD is much more prevalent than familial AD and its exact cause is still 
unknown. The occunence of sporadic AD increases with age and is the most common 
fonn of senile dementia (1). CmTently, the only genetic factor that con·elates with the 
sporadic fonn of AD is the possession of the E4 allele type at the apolipoprotein E (apoE) 
locus on chromosome 19 (1) . ApoE is a major protein of the lipoprotein transfer system 
and plays a pivotal role in lipid transport in circulation. ApoE also plays a major role 
outside of the CNS in atherosclerosis and dyslipidemia (9). In the brain, apoE is 
synthesized primatily by astrocytes, although microglia and neurons also play a minor 
role in the synthesis of the lipoprotein. Possession of the E4 allele does not necessarily 
mean the individual will develop AD. However, its presence is associated with an 
increased tisk of developing sporadic AD and contributes to an earlier onset of the 
disease as well as a more rapid disease progression (1). Individuals heterozygous for the 
e4 allele have a three-fold increase in risk for sporadic AD and homozygotes have a 12-
18 fold highertisk (10). 
1.4 Amyloid Cascade Hypothesis 
One hypothesis for the onset of AD is the amyloid cascade hypothesis (11). It 
states that presence of beta amyloid, a main component of senile plaques, is the initiating 
event, leading to neuronal degeneration, neurofibrillary tangles, vascular damage, and 
cognitive impainnent eventually progressing to dementia (11). The mutation associated 
with familial AD suppotis this hypothesis in that it is caused by mutations for both the 
amyloid precursor protein (APP) and the presenilin-1 and presenilin-2 gene, leading to 
increased beta amyloid deposition. People with Down's syndrome who possess an extra 
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APP gene develop beta amyloid plaques early in life (12) . This suppmis the hypothesis 
that overexpression of APP leads to deposition of beta amyloid. It was once believed that 
beta amyloid was an abnonnal protein found only in senile plaques, however, it was 
discovered that beta amyloid is produced dming nmmal cell metabolism, and is cleaved 
from APP by P-secretase and Y-secretase (2). Soluble beta amyloid is believed to fonn 
beta-pleated sheets, which eventually deposit to fonn plaques (2). Severity of disease in 
familial AD correlates directly with amount ofbeta amyloid deposition. This is not 
always the case with sporadic AD. However, aggregations of amyloid plaques may be 
observed in cases of sporadic AD, as well as cognitively nonnal aged individuals. In 
individuals that progress to AD, the amyloid cascade hypothesis suggests that beta 
amyloid leads to neuronal degeneration and may also be the initiating factor in the 
inflammatory cascade that is seen in AD. 
1.5 Neuro-inflammation in AD 
The presence of inflammation at sites of amyloid plaques and neurofibrillary 
tangles has been observed in pathology of AD. Microglia, the resident macrophages of 
the central nervous system, work to clear beta amyloid from the CNS by phagocytizing 
and internalizing the protein (13). Microglia produce nitric oxide, reactive oxygen 
species (ROS), pro-inflatmnatory cytokines, and prostaglandins in the presence of beta 
amyloid (14). Astrocytes are the most abundant glial cells in the human brain and have 
more specialized functions than microglia. Namely, astrocytes act as suppmiive cells to 
the endothelial cells of the blood brain barrier, supply nuttients to nervous tissue, 
maintain the extracellular ion balance, and assist in healing and repairing the brain and 
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spinal cord following traumatic injury (15). Similar to microglia, astrocytes also secrete 
various pro-inflammatory molecules such as interleukins, prostaglandins and complement 
factors, and may become activated by nearby activated microglia as a "bystander effect" 
(13, 15). In addition to the previously described functions, astrocytes play a direct role in 
the deposition and clearance of beta amyloid. This results in a positive feedback loop for 
the generation of amyloid (13) . Neurons were once thought to not play a role in 
neuroinflammation. However, it was recently discovered that neurons contribute to the 
production ofneuroinflammatory products in AD (15) . Neurons also produce several 
chemokines and cytokines, such as IL-l, IL-6 and TNF-alpha. Specific chemokines 
produced by neurons actually act as messengers between neurons and glial cells such as 
macrophage-inflmmnatory protein 1-a, monocyte chemoattractant protein-1, and 
macrophage colony stimulating factor (15, 16). Therefore, it is hypothesized that the 
deposition of beta amyloid may stimulate the inflatmnatory response that is initiated by 
the activation of glia. Secretion of pro-inflammatory substances, including IL-l, IL-6, 
and TNF-alpha by activated glia may lead to neuronal degeneration and eventually cell 
death (17) . 
IL-l is an immunoregulatory cytokine that is overexpressed early in plaque 
fonnation and is believed to be the most important cytokines in AD (18-20) . IL- l may 
promote the synthesis and processing of APP, thereby promoting the production and 
deposition of amyloid into plaques (18, 19). IL-l is also believed to promote SlOO beta 
overexpression, a neurite growth promoting cytokine that is produced by reactive 
astrocytes (I 8) . 
6 
IL-6 is a proinflammatory cytokine that induces acute phase proteins (a class of 
proteins whose plasma concentration increases or decreases in response to inflammation), 
acts as a pyrogen, and increases vascular permeability, lymphocyte activation, and 
antibody synthesis (18). In mice, elevated levels ofiL-6 have been shown to cause CNS 
damage and behavioral deficits. Levels of IL-6 have also been shown to be increased in 
the brain of AD patients (19). IL-6 may also play a role in APP synthesis, as well as 
transcription and expression of this protein (18) 
After exposure to beta amyloid, TNFa has been shown to be elevated in AD 
semm, CSF, cortex and glial cell cultures and is repmted to kill human cmtical neurons 
when in excess (18, 19). TNFa produces its effects tlu·ough two receptors, the p55 TNF 
receptor and the p75 TNF receptor. The p55 TNF receptor is believed to have an 
intracellular "death domain" that contributes to cell death when activated. In contrast, the 
p75 TNF receptor plays a protective role in neuronal survival. The expression ratio ofthe 
two TNFa receptors may regulate neuronal death and survival (18, 20). 
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Although these inflammatory events are initiated in response to deposited beta amyloid, 
the stimulus for beta amyloid deposition is still unknown. 
1.6 Infection in AD 
It has been proposed that infection could possibly initiate the inflmmnatory 
cascade of AD (8). A number of microbes have been studied as tisk factors in the 
development of AD, including Borrelia burgd01jeri, Helicobacter pylori (H. pylori), and 
Chlamydia pneumoniae (C. pneumoniae ). Herpes simplex vims 1 (HSV -1) has been 
suggested as a risk factor for the development of AD in people expressing the apoE e4 
(8). 
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1.6.1 Herpes Simplex-] 
HSV-1 is a common virus affecting between 40-80% of people worldwide (21). 
Although it typically infects the oro facial region, HSV -1 is also implicated in keratitis, 
genital herpes, and encephalitis (21). HSV -1 establishes a life-long infection in the 
peripheral nervous system of most individuals after primary infection (22). HSV-1 may 
enter the brain and cause a latent infection that reactivates sporadically in the same 
regions that are implicated in AD. This virus enters nerve ganglia through axonal 
retrograde transpmi and reactivates periodically to cause recurrent infections at the initial 
infection site (21) . Animal studies found that latent intranasal or corneal infection with 
HSV -1 was associated with focal chronic inflammation and oxidative damage in the brain 
(22). Intracerebral injection of this virus also led to encephalitis and death (22). 
Viral DNA was found to be associated with amyloid plaques in the brains of AD 
patients (21). Another study also showed that beta amyloid deposits are present in the 
mouse brain after HSV-1 infection, fmiher supporting HSV-1 infection as a causative 
agent in AD (23). Combined, these studies provide evidence that HSV-1 can cause a 
clu·onic latent infection in the human brain tlu·ough the nasal route, and cause clu·onic 
inflammation like that observed in AD. 
1.6.2 Spirochetes 
Spirochetes are fi·ee-living or host-associated helical gram-negative bacteria that 
cause latent infection in humans. A study by Miklossy and coworkers found unidentified 
spirochetes in the blood, CSF, and brains of 14 AD patients that were absent in controls 
(22, 24). They found Borrelia burgd01jeri, a type of spirochete that causes Lyme disease, 
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co-localized with beta amyloid deposits (22, 24). Another study showed that introducing 
neuronal and glial cells to Borrelia burgd01jeri and its lipopolysaccharide in vitro caused 
an increase in beta amyloid and hyper-phosphorylated tau (22, 23). These studies indicate 
that infection with this bacterium may trigger the fonnation and deposition of beta 
amyloid, and this event may lead to the amyloid plaques that are seen in AD. 
1.6.3 Helicobacter pylori 
Helicobacter pylori are gram-negative bacte1ia that colonize the gastric mucosa. 
H pylori has been linked with various digestive diseases, and is the causative agent of 
peptic ulcer disease. Vascular disorders caused by vascular dysregulation, atherosclerosis, 
hypertension, cardiovascular and/or cerebrovascular ischemia, and stroke has also been 
associated with H pylori (25). These conditions impair the blood brain barrier and, 
therefore, are all risk factors for AD. 
1.6.4 Chlamydia pneumoniae 
Another bacterium that causes inflammation and has been implicated in AD, is 
Chlamydia pneumoniae (7). C. pneumoniae is an obligate intracellular bacterium that 
infects the oral and respiratory mucosa. This organism is seen in common respiratory 
infections such as bronchitis and sinusitis, and also in severe, chronic infections such as 
chronic obstmctive pulmonary disease (COPD) (26, 27) . 
As with all species of Chlamydia, C. pneumoniae undergoes a biphasic 
development cycle during growth. Bacterial multiplication of all species of chlamydia 
occurs within a vacuole or 'inclusion' (28). The first stage of development is called the 
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elementary body (EB), and is the infectious, extracellular form of the bacterium. The EB 
typically infects epithelial cells, however, it can also infect astrocytes, microglia, and 
neurons (29). The EB attaches to a host cell by electrostatic binding and is taken into the 
cell by endocytosis. Within the cell, the EB stays within a phagosome, and then enters the 
reticulate body (RB) stage, in which it becomes metabolically active (29, 30). The RB 
will undergo many rounds of cell division via binary fission before the active stage ends, 
taking about 2-3 days, and enter back into the EB fonn (29, 30). The EB fonn then exits 
the host cell via lysis or exocytosis and the infection continues, leaving the host cell 
intact. This process allows the bacterium to cause a silent, chronic infection. Chlamydia 
species may leave the replicative life cycle and enter a persistent state in response to 
specific host stimuli (30). These stimuli include treatment with specific cytokines such as 
interferon-gamma, which is induced as a result of pro-inflatmnatory cytokine production, 
antibiotics, or a restriction of nutrients. In this state, metabolic activity is reduced and the 
organism does not respond to antibiotics (30). In several studies, chronic persistent 
infections of C. pneumoniae in vascular cells led to pro-proliferative and pro-
inflammatory phenotypes within the affected vasculature. Attempts to eliminate this 
organism in patients with cardiovascular disease were not successful. This indicates that 
the persistent state of Chlamydia is refractory to antibiotic treatment (31). This is 
important because it allows the bacterium to avoid itmnune system attack. Research 
conducted by Hatmnerschlag et al (2000) discovered persistent infection with C. 
pneumoniae after acute respiratory infection in five patients in a peliod of up to 11 
months, despite treatment with multiple courses of antibiotics, and two of these five 
patients displayed persistence for 7-9 years (27). Organisms in the persistent state elicit 
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chronic disease, such as chronic pulmonary diseases. C. pneumoniae can also disseminate 
and promote chronic inflammation at sites not associated with the respiratory tract, such 
as the cardiovascular system and the central nervous system (29) . 
Persistence of the organism has been observed in both human isolates of 
chlamydia, Chlamydia trachomatis and Chlamydia pneumoniae. C. trachomatis is the 
most common sexually transmitted infection worldwide and is the main cause of 
preventable blindness (1 8). Similar to C. pneumoniae, infection of epithelial cells with C. 
trachomatis elicits an inflammatory response. Although clearance of this organism 
through inflammation is usually successful, some individuals can develop clu·onic 
inflammation leading to tissue damage (18). C. trachomatis infection has been 
implicated in inflatmnatory diseases such as ReA, pelihepatitis, and pelvic inflammatory 
disease (32-34) . Both ReA and perihepatitis provide evidence for the ability of this 
organism to disseminate from its site of primary infection. Monocytes may phagocytose 
this bacterium and catTy it to sites distant fiom the site of infection (33) . Ifthe organism 
has the ability to infect the joints after genito-urinary infection, then it not only can cause 
joint inflatmnation, but can also disseminate to other sites. This affect was observed in a 
rat model in which there was significant dissemination of C. trachomatis from the joints 
to the liver and spleen (35) . The ability of C. trachomatis to disseminate throughout the 
body would be necessary for this organism to infect brain tissue and possibly cause AD 
pathology. 
Chlamydiallipopolysaccharide (LPS), heat shock proteins, and outer membrane 
proteins cause the inflammatory response (29). Infection with this organism also may up 
regulate cytokine production in neighboring cells. Pro-inflammatory cytokines associated 
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with chlamydia! infection include IL-l~, TNFa, IL-6, and IL-8 (8, 36). IFN-Y and IL-12 
were also found at sites of chlamydia! infection. Chlamydia! infection may cause the 
inflammatory response directly by up regulating cytokine production, or the immune 
response to infected cells may drive inflammation through cytokine producing 
macrophages/lymphocytes (8, 29) The inflammatory cytokines and chemokines are 
known to recmit neutrophils and other leukocytes. Neutrophils destroy accessible EBs 
and release matlix metalloprotease (MMPs) molecules and neutrophil elastase, which 
lead to tissue damage (36). The fact that chlamydia can generate a persistent infection 
and promote an inflammatory response fmiher suppmis the hypothesis that infection with 
Chlamydia pneumoniae may play a role in the development of sporadic AD (7). 
1.7 Chlamydia pneumoniae and Accompanying Pathologies 
C. pneumoniae is able to infect a wide variety of eukaryotic cell types, and almost 
all people will be infected with this bacterium by the age of 20. Reinfection is cmmnon; 
with a higher antibody count in older populations (1 7). As previously stated, this 
organism is known to cause acute respiratory infections, such as pneumonia, sinusitis and 
bronchitis. C. pneumoniae has also been implicated in chronic respiratory diseases, such 
as asthma, sarcoidosis, and chronic obstmctive pulmonary disease (8, 17). C. 
pneumoniae has been associated with non-respiratory diseases, including atherosclerosis, 
reactive mihritis, multiple sclerosis, as well as several diseases affecting the central 
nervous system (7, 8, I 7). In a study by Hannu et al, (1999) 35 of 60 patients had reactive 
arthritis with evidence of a preceding infection with C. pneumoniae. Additionally, four 
ReA patients had serological evidence of recent C. pneumoniae infection and three ofthe 
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four patients had recent symptoms of a lower respiratory infection that preceded mth1itis 
(37) . 
C. pneumoniae has been identified in atheromatous plaques in the carotid, a01ta 
and coronary mteries of people with coronary syndrome (7, 38). C. pneumoniae may 
exacerbate atherosclerosis by activating toll-like receptors on macrophages and dendritic 
cells (DCs) that populate the aortic sinus in these patients. C. pneumoniae can both 
induce the inflammatory process and intensify the existing inflammatory process in the 
a01tic sinus (38). 
In another study by Sriram, et al, (1999) C. pneumoniae infection was found in 
patients with newly diagnosed relapsing-remitting MS as well as in patients with 
progressive MS, but was not found in control patients with other neurological disease. 
64% (24 of37) of these patients were positive for C. pneumoniae in the CSF. This 
organism was found in both relapsing-remitting MS and progressive MS providing 
evidence that infection of the CNS occurs early and persists throughout the course of the 
disease (39). The fact that C. pneumoniae is implicated in these diseases provides 
evidence that this organism is found at sites other than the site of primary infection. This 
research indicates that C. pneumoniae can disseminate systemically and cause infection at 
sites other than the respiratory epithelium. 
1.7.1 Chlamydia pneumoniae and Alzheimer's Disease 
The first study associating C. pneumoniae infection with AD pathology 
discovered chlamydia genetic material through PCR analysis in 90% (17 of 19) of LOAD 
brains post mortem. In contrast, 18 of 19 control samples were PCR negative for this 
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genetic material. Regions implicated in AD, including hippocampus, temporal cmiex and 
prefrontal cmiex were positive for C. pneumoniae (7, 29). Fmihennore, immunolabeling 
identified this organism within pericytes, microglia, and astroglia, and these cells co-
localized with both amyloid plaques and neurofibrillary tangles (1, 8). These findings 
were also consistent with the apoE genotype as a risk factor for the development of 
sporadic AD. The majority of patients who were PCR positive for chlamydia antigen 
possessed at least one 84 allele. Four patients with chlamydia} DNA in the temporal lobe, 
prefrontal coliex, and cerebellum displayed the most severe neuropathology, and tlu·ee of 
these four patients had an 84 allele (7, 8). Cytokine expression was also up regulated as a 
result of chlamydia infection, which can induce chlamydia to enter into a persistent state 
and lead to a prolonged inflanunatory response (8). Inflammation in response to infection 
with C. pneumoniae could stimulate the processing and deposition of amyloid in the CNS 
(40). 
Research by Little, et al (2004) developed a mouse model to dete1mine whether 
infection with C. pneumoniae could induce neuropathology similar to what is seen in 
sporadic AD. Non-transgenic BALB/c mice were infected with C. pneumoniae, which 
induced AD-like pathology in the absence of predisposing genetic factors. The organism 
was found in the olfactory epithelia as well as the olfactory bulbs. This finding suppmis a 
nasal route of transmission into the CNS. Amyloid deposits that resembled human AD 
plaques were also found. An inflammatory response was detennined by the detection of 
activated astrocytes, some of which co-localized with the amyloid deposits (40). The 
reactive astrocytes may be responding to the amyloid deposits or to the C. pneumoniae 
antigen directly. Inflammation may stimulate the processing of amyloid, as well as inhibit 
the replication of C. pneumoniae (40). However, activated glial cells may also have 
neurotoxic effects. Pro-inflammatory mediators released by activated glial cells could 
lead to CNS injury (18). 
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Research into inflammatory processes in AD discovered that microglia in the AD 
brain express major histocompatibility complex type II (MHCII) cell surface glycoprotein 
(18). However, microglia fi-om non-demented (ND) brains showed substantially 
decreased MHCII expression (18). Additionally, when exposed to beta amyloid deposits 
in vitro, cultured AD and ND microglia show increased MHCII immuno-reactivity. This 
suggests that exposure to beta amyloid leads to microglial activation, and is a cmcial step 
in the initiation of inflatmnation seen in AD (18). 
Beta amyloid was once believed to have no nmmal physiological function. 
However, it was discovered that this peptide actually acts as a ligand for different 
molecules and receptors that respond to enviromnental stressors (41). Beta amyloid 
belongs to a group of antimicrobial peptides (AMPs), which function in the innate 
immune system, and can respond to both Gram-negative and Gram-positive bacteria (41) . 
Research by Soscia et al (41) discovered that the CNS could initiate a response to foreign 
pathogens tlu·ough AMPs and the innate immune response. Beta amyloid may act as part 
of an immune response to clear C. pneumoniae infection fi-om the CNS. However, as an 
intracellular bacterium, C. pneumoniae can remain viable in host cells for prolonged 
peliods by evading lysosomal degradation (8). The persistent state of this organism, along 
with clu·onic reactivation, disrupts the balance of beta amyloid deposition and clearance 
that was established in the amyloid cascade hypothesis (11). C. pneumoniae may be the 
initial stimulus for beta amyloid production. However, the unique characteristics of tllis 
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organism lead to an unresolved infection and, subsequently, chronic inflammation. This 
may lead to production and deposition of amyloid and AD pathology. 
The mechanism by which C. pneumoniae enters the CNS is still unknown. One 
hypothesis states that this organism may infect monocytes in the lungs and spread the 
infection through the peripheral circulation to the brain through the BBB (29). Research 
by Macintyre et al (2003) utilized i1mnunohistochemistry to identify C. pneumoniae in 
the brain blood vessels as well as in the lumen of these vessels in AD patients (42). 
Additionally, C. pneumoniae was identified at the level of BBB microvasculature. This 
organism was shown to infect human brain endothelial cells (HBMECs ), which led to 
increased expression of surface adhesion molecules VCAM-1 and ICAM-1. Additionally, 
infection of monocytes with C. pneumoniae led to down regulation of occludin, the tight 
junctional protein, at 72 hours post infection. These changes increased the probability for 
transmigration of infected monocytes into the brain (29, 42). 
Another possible route of transmission is through the olfactory pathway. C. 
pneumoniae is a respiratory pathogen, giving it a direct cmmection to the olfactory 
neuroepithelium of the nasal olfactory system (29). PCR analysis ofbrain tissue 
discovered C. pneumoniae genetic material in these structures. The infection may then 
progress to the olfactory bulbs, and transport to the entorhinal cmtex, hippocampus and 
temporal cmtex, which interestingly, is also where some of the earliest pathology is 
observed in AD (29). The role of C. pneumoniae in inflammatory diseases provides 
further support for the hypothesis that infection with this organism can cause an 
inflatmnatory response, leading to AD-like pathology and, eventually, symptomatic AD. 
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1.8 Dissemination of C. pneumoniae From the Site of Primary Infection 
Although debated, the association between C. pneumoniae and diseases such as 
MS, AD and atherosclerosis, provide evidence that this bacterium can disseminate 
systemically and cause infection in many areas of the body. C. pnewnoniae may use the 
vasculature to disseminate. This organism was found in the spleen, aorta, and abdominal 
lymph nodes, supp01iing that it can disseminate via monocytes to sites distant from 
primary infection through the vasculature (30). The discovery of chlamydia in synovial 
fluid of patients with ReA also suggests that monocytes may be involved in carrying tllis 
organism to the joints distant from the initial infection (33). Immunohistochemical 
staining found cells infected with chlamydia associated with blood vessels in the brain 
(7, 29). The ability of this organism to cause a persistent infection in peripheral blood 
monocytes (PBMCs) may fmiher enable these cells to cross the blood-brain batTier. In an 
in vitro model, infection with C. pneumoniae caused human brain micro-vascular 
endothelial cells (HBMECs) to enhance expression of surface adhesion molecules ICAM-
1 and VCAM-1 and led to a three-fold increase of infected monocytes through the 
infected ban·ier in relation to uninfected monocytes through an uninfected endothelial 
barrier. This suggests that infection of monocytes and micro-vascular endothelial cells 
with C. pneumoniae may facilitate increased entry of C. pneumoniae into the CNS from 
the systemic circulation (29). The ability of this organism to disseminate to sites distant 
from that of the primary infection and to elicit a chronic inflmmnatory response, along 
with the previous research confinning C. pneumoniae in AD brain tissue, supp01i a role 
of C. pneumoniae infection in the development of AD-like pathology. 
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1.9 Chlamydia muridarum and AD-like Pathology 
To answer the question if AD-like pathology is specific to infection with C. 
pneumoniae, we utilized C. muridarum (MoPn), a mouse adapted pneumonitis 
genetically similar to C. trachomatis. However, unlike C. trachomatis, which infects the 
genital tract, MoPn infects the respiratory tract, making it more similar to C. pneumoniae 
in terms of the location of infection (43) In a 2004 study by Little, et al, C. pneumoniae 
was isolated from human AD brain tissue and intranasally inoculated into BALB/c mice. 
BALB/c mice were chosen because they are susceptible to C. pneumoniae infection and 
can establish a chronic infection. These mice are also non-transgenic, indicating that they 
do not have any human genes making them susceptible to early development of AD 
pathology. Mice were sacrificed at 1, 2 and 3-month post infection and analyzed for 
chlamydia antigen and amyloid burden using immunohistochemistry and light 
microscopy. This produced a progressive pathology in the brains ofBALB/c mice (40). 
In another study conducted by Little, et al, a laboratory strain of C. pneumoniae (AR39) 
was introduced intranasally into BALB/c mice using the same procedure as the 2004 
study. However, the laboratory isolate produced a transient pathology (44). 
To determine if this pathology is specific only to C. pneumoniae, an in vivo 
passaged strain of C. muridarum and a laboratory strain of C. muirdarum was introduced 
intranasally into the brains ofBALB/c mice. Results indicated there was no significant 
difference between the two isolates of C. muridarum. However, titer positive mice 
showed a greater burden of chlamydia antigen and amyloid deposition than titer negative 
mice. The cunent research will analyze glial cell activation in response to chlamydia 
infection and amyloid burden. 
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1.10 Objectives and Hypothesis 
Based on the previous work indicating that infection with C. muridarum, a mouse 
variant of chlamydia, leads to AD-like pathology, we hypothesize that 
immunohistochemical analysis will indicate that infected brain tissue will have greater 
glial cell burden in C. muridarum infected mice relative to titer negative C. muridarum 
infected tissue. 
The focus of this research is to determine if astrocytes are activated in brain tissue 
of mice infected with C. muridarum. Immunohistochemistry and microscopy will be used 
to determine if glial cells are more abundant in the infected mouse tissue. Mice infected 
with C. m.uridarum displayed chlamydia antigen and amyloid deposits in the brain tissue. 
BALB/c mice were intranasally infected with various known concentrations of C. 
muridarum isolates, plagued in vivo passaged C small Weiss (CSW) and plagued stock 
mouse pneumonitis Weiss (MoPn Weiss). 
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2. Materials and Methods 
2.1 Chlamydia muridarum 
Two isolates of Chlamydia muridarum were used to intranasally infect BALB/c 
mice. Chlamydia muridarum is a mouse variant of Chlamydia trachomatis. C small 
Weiss (CSW) and mouse pneumonitis Weiss, (MoPn Weiss) are two different isolates of 
C. muridarum that were used to infect different experimental groups of mice. C small 
-weiss is an isolate ofMoPn that was passaged in the urogenital tract of mice 3 sequential 
times to increase its vimlence. MoPn Weiss is a plaque pmified, presumed monoclonal 
stock isolate. 
2.2 Infection of Mice and Tissue Preparation 
Mice were intranasally infected with either C small Weiss or mouse pneumonitis 
Weiss in the lab of Dr. Kyle Ramsey at Midwestern University in Chicago. Group A 
mice were intranasally infected with 1 x 102 or 1 X 105 IFU's ofC small Weiss. Group B 
mice were intranasally infected with 1 x 101 or 1 x 105 IFU of MoPn Weiss (Tables 1 & 
2). Mice were sacrificed 60 days post infection, brains were removed and immersion 
fixed in 4% paraformaldehyde and provided to this research group. Brain tissue was 
embedded in paraffin, and coronally serial sectioned at 7-10 micron thickness. 
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Table 1: C Small Weiss (MoPn in vivo) Experimental Group 
Name C. muridarum Inoculum Duration of Infection Titer 
Isolate (IFU) 
3A6 csw 100 60 days Negative 
3A8 csw 100 60 days Negative 
6A4 csw 100,000 60 days 1:5120 
6A6 csw 100,000 60 days 1:10240 
6A7 csw 100,000 60 days 1:5120 
6A8 csw 100,000 60 days 1:5120 
Table shows experimental design for the CSW group. Mice were intranasally infected with either 100 or 
100,000 IFU's of CSW antigen. Seroconversion titers of animals were taken to detennine if infection was 
established. 
Table 2: Mouse Pneumonitis Weiss (MoPn Stock Solution) Experimental Group 
Name C.muridarum Inoculum Duration of Infection Titer 
Isolate (IFU) 
2B1 MoPn Weiss 10 60 days Negative 
6B1 MoPn Weiss 100,000 60 days 1:10240 
6B5 MoPn Weiss 100,000 60 days 1:20480 
6B6 MoPn Weiss 100,000 60 days 1:20480 
6B8 MoPn Weiss 100,000 60 days 1:20480 
6B9 MoPn Weiss 100,000 60 days 1:10240 
6B10 MoPn Weiss 100,000 60 days 1:10240 
Table shows experimental design for the MoPn Weiss group. Mice were intranasally infected with either 10 
or 100,000 IFU's ofMoPn Weiss antigen. Seroconversion titers of animals were taken to detemline if 
infection was established. 
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2.3 Mouse Brain Tissue 
A total of 12 coronal brain sections were immunolabeled per mouse. Ten sections 
were labeled with Glial fibrillary acidic protein (GF AP) (Cat #180063) specific antibody 
and two sections did not receive primary antibody and were used as a negative control. In 
order to sample from areas throughout the brain, serial sections were selected every 70-
100 microns from rostral (bregma 0 mm, yellow 0) to caudal (bregma -4.82mm, blue 4) 
(Figure 2). 
Figure 2: Anatomic Location of Representative Coronal Sections 
Top itnage represents the area of the brain where coronal sections were chosen every 7 to 10 
microns. Sections rostral (red circles) to bregma (yellow circle) and caudal to bregma (blue 
circles) are displayed. Panel B displays particular regions of interest, related to Alzheimer's 
disease. Images were taken from the Mouse Brain Library (The Mouse Brain Library - Search the 
library. (n.d.). Retrieved July 24, 2015.) 
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2.4 Antibodies 
Mouse brain tissue was previously immunolabeled for the presence of Chlamydia 
muridarum utilizing a mouse monoclonal antibody. Beta amyloid protein was detected 
utilizing a rabbit polyclonal antibody sc-9129 and a mouse monoclonal antibody 6E1 0 
specific for amyloid antigen. The primary antibody specific for GF AP utilized to detect 
glial cells was rabbit anti-GFAP (Invitrogen, Fredelick, MD) at a stock concentration of 
151 .67 mg/L and was used at a working dilution of 1 :100. To visualize the respected 
antigen alkaline phosphatase conjugated goat anti-rabbit lg secondary antibody (Life 
Technologies, Carlsbad, CA) was utilized at a concentration of 1.25 micrograms/ml 
(1 :400). Antibodies were diluted to working concentration using 2% fetal bovine semm 
and phosphate buffered saline. 
2.5 Immunohistochemistry 
Paraffin embedded mouse brain coronal sections were rehydrated plior to the 
immunohistochemistry procedure. The rehydration consisted of 3 minute washes in 
xylene (x3), followed by a series of graded alcohol dilutions: 100% ethanol for 3 minutes 
(x2), 90% ethanol for 3 minutes (x1), 70% ethanol for 3 minutes (x1) (Electron 
Microscopy Sciences, Fmi Washington, PA). Next, slides were washed in sterile filtered 
DI H20 for 3 minutes (x2). Slides were then placed in Citra antigen retrieval buffer 
(BioGenex, San Roman, CA) and steamed at high pressure for 20 minutes at 120 degrees 
Celsius in a 2010 Retreaver (Pick Cell Laboratories, Amsterdam, Netherlands). Slides 
remained in antigen retrieval buffer overnight at room temperature. 
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On day 2, slides were removed fi:om antigen retrieval buffer and washed with 
phosphate buffered saline pH 7.4 (PBS) for 5 minutes (x3). Next, Alkaline Phosphatase 
Horseradish Peroxidase was applied to slides for 5 minutes to quench endogenous 
enzymatic activity. Slides were washed again, 5 minutes with PBS (x3). 
Next, slides were blocked 15 minutes (x 1) with 2% heat inactivated fetal bovine 
semm (FBS) (Mediatech, Herndon, VA) in PBS. Primary antibody rabbit anti-GFAP or 
blocking buffer (2° group only) were applied to conesponding sections and placed in a 
humidified chamber at 37° C for 90 minutes. Slides were then washed 5 minutes (x3) 
with PBS and blocked 15 minutes (x2) with 2% FBS/PBS. Goat anti-rabbit Ig secondary 
antibody was applied to each slide and then incubated for 60 minutes in a humidified 
chamber at 37° C. 
After the second incubation, slides were washed for 5 minutes (x3) with sterile 
filtered molecular grade DI water (DI H20). Slides were developed for 15 minutes using 
purple one component (BioFX, Eden Prailie, MN). Next slides were washed with DI H20 
5 minutes (x3) and PBS 5 minutes (xl), followed by counterstaining with acidified 
Ranis's Hematoxylin (Mercury free) applied for 1 minute. The slides were rinsed with 
DI H20 then washed with PBS for 5 minutes to produce a color change. Finally slides 
were washed 5 minutes (x3) with DI H20 then wiped down and air-dried. Once dry, 
slides were mounted with Glycergel mounting media (Dako) and cover slipped. 
2.6 Microscopic Analysis and Quantification of Glial Cell Number 
Tissue was examined using lOx ocular and 4x and lOx power objectives on a 
Nikon Eclipse 50i microscope. Images were taken of four quadrants on each section at 
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lOx power objective (upper left, lower left, upper right, lower right). bnages were 
captured using NIS-Elements F 2.20 and imaging systems software using a Nikon Digital 
Sight DS-DM Camera. ImageJ software was used to analyze captured images to quantify 
GF AP-positive immunolabled glial cells 
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3. Results 
3.1 Experimental infection of BALB/c mice 
BALB/c mouse brain tissue was analyzed at 60-day post infection to determine 
whether activated astrocytes were present. A total of 13 mouse brains were analyzed; 6 
fi:om the intranasal infection with C small Weiss with 2 controls and 4 expelimentals and 
7 from the intranasal infection with mouse pneumonitis Weiss with one control and 6 
experimentals. 
3.2 Analysis of GFAP specific labeling inC small Weiss 
The C small Weiss group (n=6) consisted of2 titer negative controls that did not 
seroconvert, indicating that an infection was not established, and 4 titer positive mice 
(titers 1 :5120 and 1:1 0240). A comparison of the dentate gyrus, an area that displays 
pathology in AD, displayed activated glial cells in the titer negative, 1:5120 titer positive, 
and 1:10240 titer positive groups (Figure 3 A, B, C). The entorhinal cmiex (EC), one of 
the first areas affected in AD, showed activated glia in the titer negative group and the 
1:10240 titer group, but is not as abundant in the I :5120 titer group (Figure 4 A, B, C). A 
compalison of the thalamus shows substantial glial cell quantity across the three groups 
(Figure 5 A, B C). 
3.3 Analysis of GFAP specific labeling in mouse pneumonitis Weiss 
The mouse pneumonitis group (n=7) consisted of one titer negative infected 
mouse and 6 titer positive infected mice (titer 1:10240 and 1 :20480). A comparison of the 
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dentate gryus displayed activated glial cells in all three groups (Figure 6 A, B, C). The 
entorhinal cortex displayed greater glial cell quantity in the titer negative and the 1 :20480 
titer group compared to the 1:10240 titer group. However, some glia are still observed in 
the 1: 10240 titer group. (Figure 7 A, B, C). A comparison of the thalamus displayed great 
glial cell amounts across the titer negative, 1 :20480 and 1:10240 titer groups (Figure 8 A, 
B, C). 
3.4 Analysis of astroglia burden: C small Weiss (CSW) 
A total of 10 slides per mouse were immunolabeled for activated astroglia using 
GF AP labeling antibody and analyzed using light microscopy (See Materials and 
Methods). Two mice in the C small Weiss (mouse pneumonitis in vivo) group were given 
an infectious dose of 102 IFU and were titer negative for seroconversion, with glial cell 
counts of 224 and 612 respectively (Figure 9). One mouse was titer negative for 
seroconversion in the mouse pneumonitis Weiss group and therefore was grouped with 
the two-titer negative mice in the C small Weiss group. The titer negative mice had a 
mean glial cell count of 421 with a standard deviation of 194.07 (Table 3 and Table 4). 
An infectious dose of 105 IFU was given to the remaining mice in the C small Weiss 
group (6A6, 6A4, 6A7, 6A8) One mouse was titer positive for seroconversion with a titer 
of 1:10240 and a glial cell count of 483. Three mice were titer positive for seroconversion 
with a titer of 1 :5120, glial cell counts of 186, 349, and 609 respectively (Figure 9), with 
a mean glial count of381.33 and a standard deviation of213.35 (Table 3). 
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3.5 Analysis of astroglia burden: mouse pneumonitis Weiss 
A total of 10 slides per mouse were immunolabeled for activated astroglia and 
analyzed using light microscopy (See Materials and Methods). One control mouse in the 
mouse pneumonitis stock group was given an infectious dose of 102 IFU and was titer 
negative for seroconversion with a glial cell count of 427 (Figure 10) (Table 4). The titer 
negative mice in both groups were grouped together with a mean glial cell count of 421 
and a standard deviation of 194.07 (Table 3 and Table 4). The remaining mice were given 
an infectious dose of 105 IFU. Three mice were titer positive for seroconversion with a 
titer of 1:10240 and glial cell counts of304, 318, and 405 respectively (Figure 10), with a 
mean glial count of 342.33 and a standard deviation of 54.72 (Table 4 ). Three mice were 
titer positive for seroconversion with a titer of 1 :20480 and glial counts of 809, 845 and 
2034 (Figure 10), with mean glial count of 1229.33 and a standard deviation of697.09 
(Table 4). 
3.6 Analysis of amyloid deposits: C small Weiss 
Previous work was done to detennine amyloid pathology in the C small Weiss 
group. A total of20 slides per mouse were i1mnunolabeled for beta amyloid and analyzed 
using light microscopy. Two mice were titer negative mice and did not seroconve1i and 
displayed an amyloid burden of2 and 4 deposits, respectively (Table 3) (Figure 9). Tlu·ee 
mice seroconve1ied with a titer of 1:5120 and had amyloid deposits ranging from 10 to 
112 (Table 3) (Figure 9). One mouse seroconverted with a titer of 1:10240 and had an 
amyloid burden of 52 deposits (Table 3) (Figure 9) 
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3.7 Analysis of amyloid deposits: mouse pneumonitis Weiss 
Previous work was done to determine amyloid pathology in the mouse 
pneumonitis Weiss group. A total of20 slides per mouse were immunolabeled for beta 
amyloid and analyzed using light microscopy. One mouse was titer negative, indicating 
that it did not seroconvert and had an amyloid burden of2 deposits (Table 4) (Figure 1 0). 
Tlu·ee mice seroconvetted with a titer of 1:10240 and had amyloid deposits ranging from 
13 to 23. Three mice seroconvetted with a titer of 1 :20480 and had amyloid deposits 
ranging fi·om 4 to 9 (Table 4) (Figure 1 0). 
3.8 Analysis of C muridarum antigen: C small Weiss 
The presence of C. muridarum antigen was previously determined in the C small 
Weiss group. A total of 3 0 slides per mouse were immunolabeled for C. muridarum and 
analyzed using light microscopy. Two mice were titer negative mice indicating they did 
not seroconvett and had a C. muridarum antigen burden of 1 and 21 , respectively (Table 
4) (Figure 11). Tlu·ee mice seroconverted with a titer of 1:5120 and had C. muridarum 
antigen ranging fi'om 5 to 121 (Table 4) (Figure 11 ). One mouse seroconverted with a 
titer of 1:10240 and had a C. muridarwn antigen burden of 43 (Table 4) (Figure 11). 
3.9 Analysis of C muridarum antigen: mouse pneumonitis Weiss 
C. muridarum antigen burden was previously detennined in the mouse 
pneumonitis Weiss group. A total of30 slides per mouse were immunolabeled for C. 
muridarum and analyzed using light microscopy. One mouse was titer negative, 
indicating that it did not seroconvett and had a C. muridarum antigen burden of2 (Table 
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4) (Figure 12). Three mice seroconvelied with a titer of 1:10240 and had C. muridarwn 
antigen ranging from 29 to 186 (Table 4) (Figure 12). Three mice seroconverted with a 
titer of 1 :20480 and had C. muridarum antigen ranging from 0 to 10 (Table 4) (Figure 
12). 
3.10 Summary of Results 
A total of 13 BALB/c mouse brains were analyzed for astrocyte specific labeling. 
Mice were inoculated with either the C small Weiss (n=6) or mouse pneumonitis Weiss 
(n=7) variant of C. muridarum and sacrificed at the 60-day time point. Semiquantitative, 
immunohistochemical and microscopic analysis revealed great vmiability in glial cell 
specific labeling in mice intranasally inoculated with either isolate of C. muridarum. 
Glial cell labeling ranged from 186 to 612 for the C small Weiss group and 304 to 2034 
for the MoPn group. The greatest glial cell quantity between the titer negative controls 
and the titer positive experiments was seen in mice intranasally inoculated with the 
mouse pneumonitis Weiss variant of C. muridarum. The mean glial cell count of this 
group was 427 for the titer negative group, 342.33 for the 1:10240 titer positive group, 
and 1229.33 for the 1:20480 titer positive group, respectively. This indicates an 
approximate 3-fold increase between the titer negative group and the titer positive 
1:20480 experimental group (Table 4). The C small Weiss group displayed less than a 
10% difference in glial cell amount between the two groups. The mean glial cell count of 
this group was 418 for the titer negative control, 3 81.33 for the 1 :5120 titer positive 
group, and 438 for the 1:10240 titer positive group (Table 3). 
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Figure 3 GFAP specific labeling of the dentate gyrus in CSW group tissue. 3A represents titer negative 
seroconversion tissue. 3B represents tissue with I :5I20 titer positive seroconversion. Figure 3C represents 
tissue with I: I 0240 titer positive seroconversion. GF AP specific labeling appears dark purple/black. Mag 
bar represents I 00 microns. 
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Figure 4 GF AP specific labeling of the entorhinal cortex in CSW group tissue. 4A represents titer negative 
seroconversion tissue. 4B represents tissue with 1 :5120 titer positive seroconversion. Figure 4C represents 
tissue with 1: 10240 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag 
bar represents 100 microns. 
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Figure 5 GF AP specific labeling of the thalamus in CSW group tissue. SA represents titer negative 
seroconversion tissue. SB represents tissue with 1:5120 titer positive seroconversion. Figure SC represents 
tissue with 1: 10240 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag 
bar represents 100 microns. 
... . 
i ' ) . . 
' . -
. ·-
1, -i . 
I ' 
I, ' 
• j. ' 
" .. 
: .. ' ) ' ' 
,. ,, 
, . 
- ~· . • 1~ · 
· .. 
.,. .. 
-· 
... 
• I 
' .(. 
·- ' I 
• ·"'r 
. '· . I . 
. -
' •·. 
\ . 
. ' ~.· · 
. . ..r-:. 
t ·!~ ' . 
~ • _.,t.. ' ,.,_. 
.. 
' 
' 
34 
: :·. ··y· _ .. 
.. ... . (. ·." 
• t ; ,. •• 
I c ~ • J 
• L -._ 
.· .. 
•. ·, 
·-
Figure 6 GF AP specific labeling of the dentate gyrus in MoPn group tissue. 6A represents titer negative 
seroconversion tissue. 6B represents tissue with 1: 10240 titer positive seroconversion. Figure 6C represents 
tissue with 1:20480 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag 
bar represents 1 00 microns. 
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Figure 7 GFAP specific labeling of the entorhinal cortex in MoPn group tissue. 7A represents titer negative 
seroconversion tissue. 7B represents tissue with 1: 10240 titer positive seroconversion. Figure 7C represents 
tissue with 1 :20480 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag 
bar represents 100 microns. 
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Figure 8 GF AP specific labeling of the thalamus in MoPn group tissue. 8A represents titer negative 
seroconversion tissue. 8B represents tissue with 1: 10240 titer positive seroconversion. Figure 8C represents 
tissue with 1:20480 titer positive seroconversion . . GF AP specific labeling appears dark purple/black. Mag 
bar represents 100 microns. 
C small Weiss 
3A6 0 100 224 
3A8 0 100 612 
6A4 5120 100,000 186 
6A7 5120 100,000 349 
. . . . 
D • 
421 194.07 
381.33 213.35 
1 
5 
117 
37 
• • 
4 
4 
112 
6A8 5120 100,000 609 121 10 
6A6 100,000 483 43 
Table 3: Glial cell totals for C small Weiss in vivo group. Mean values represent average glial cell count for 
all brains with the same seroconversion titer. Titer negative represents mean value for C small Weiss (n=2) 
and mouse pneumonitis Weiss (n= l). Nomenclature for individual mice (Brain) is as follows: Infectious 
dose received intranasally, isolate of C. muridarum, identifier for individual mouse. For example, mouse 
3A6 was the sixth mouse (6) that received 100 IFUs (3) ofC small Weiss (A) 
mouse 
pneumonitis 
Weiss 
• Cl • • 
: •• 
281 0 10 427 421 .07 
6810 10240 100,000 304 
681 10240 100,000 318 
689 10240 100,000 405 
686 20480 100,000 809 
688 20480 100,000 845 1229.33 697.09 
685 20480 100,000 2034 
Table 4: Glial cell totals for mouse pneumonitis Weiss group. Mean values represent average glial cell 
count for all brains with the same seroconversion titer. Titer negative represents mean value for C small 
Weiss (n=2) and mouse pneumonitis Weiss (n= l). Nomenclature for individual mice (Brain) is as follows: 
Infectious dose received intranasally, isolate of C. muridarum (A indicates C small Weiss, B indicates 
mouse pneumonitis Weiss), identifier for individual mouse. 
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Figure 9: Analysis of astroglia burden and amyloid deposits: C small Weiss (CSW). 
Y -axis represents amyloid burden per mouse. X-axis represents glial cell count per 
mouse. 
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Figure 10: Analysis of astroglia burden and amyloid deposits: Mouse pneumonitis Weiss 
(MoPn). Y-axis represents amyloid burden per mouse. X-axis represents glial cell count 
per mouse. 
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Figure 11: Analysis of C. muridarum antigen: C small Weiss. Y-axis represents C.mu 
antigen per mouse. X -axis represents glial cell count per mouse. 
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Figure 12: Analysis of C. muridarum antigen: Mouse pneumonitis Weiss. Y-axis 
represents C. mu antigen per mouse. X-axis represents glial cell count per mouse. 
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4. Discussion 
The extracellular deposition of beta amyloid, neurofibrillary tangles and activated 
glial cells leading to an inflammatory cascade are all the initiating events that eventually 
lead to the neurodegeneration that is seen in AD. The goal of this work was to determine 
glial cell response to infection with Chlamydia muridarum and the relationship relative to 
deposited beta amyloid. It was hypothesized that as amyloid deposits and chlamydia 
antigen burden increases, glial cell count will also increase. A slight inverse relationship 
was observed between glial cell count and amyloid deposits in the C small Weiss group. 
However, this trend is not as prominent as that observed in the mouse pneumonitis group. 
This finding supp01is the hypothesis that the in vivo passaged strain of C. muridarum is 
more antigenic and stimulates the host immune response more than the mouse 
pneumonitis Weiss stock isolate. In the 2004 study by Little, et al, C. pneumoniae 
isolated from human AD brain tissue and reintroduced intranasally into the brains of non-
transgenic BALB/c mice displayed a progressive AD-like pathology (40). As the 
infection advanced, the amyloid deposits in the brain increased in number and size (40). 
This con·elates with the data seen in the C small Weiss group. As the titer amount 
increased, the amount of amyloid deposits increased while glial cell counts follow a slight 
downward trend. It is hypothesized that the glial cells are not phagocytosing the amyloid 
and becoming activated, therefore this would allow the pathology to progress. In a study 
by Krabbe, et al, (20 13) an inverse con·elation was detected between amyloid plaque 
burden and microglia phagocytic activity. When stimulated with TNFa, microglia 
displayed a down-regulation of receptors involved in beta amyloid binding and 
degradation (45). 
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In this study, an inverse relationship was observed between glial cell count and 
amyloid deposits in the mouse pneumonitis Weiss group. As glial cell counts increased, 
amyloid deposits decreased. This finding is consistent with previous research. Astrocytes 
not only adhere to beta amyloid, but findings indicate they may also degrade it (46-48). 
In human AD brain tissue, it was noted that beta amyloid was present in astrocytes 
sunounding amyloid plaques (48). Hippocampal brain tissue that was incubated for 24 
hours with astrocytes displayed 40% less area occupied by beta amyloid than untreated 
tissue (48). Astrocytes, along with microglia, work to phagocytose the beta amyloid and 
clear it from the CNS. These glial cells become more abundant and activated during tllis 
process, leading to a series of changes refened to as astrogliosis (47). However, 
activation of glial cells can promote neuronal damage through the production of pro-
inflammatory cytokines. The release of these cytokines can cause dysfunction of nerve 
tenninals and loss of synapses, leading to memory decline and eventually neuronal death 
in late stages of AD (19) . 
Mouse pneumonitis Weiss, the stock isolate of C. muridarum, is hypothesized to 
be less virulent than the in vivo passaged C small Weiss isolate. When comparing a stock 
isolate and an in vivo passaged isolate of C. muridarum, Ramsey et al indicated a 
significant virulence difference in vivo as well as different growth characteristics in vitro 
(49). They discovered a greater virulence of the in vivo passaged isolate of mouse 
pneumonitis Weiss when compared to a stock isolate of the organism. A study by Little et 
al (2014) dete1mined infection with the stock isolate of C. pneumoniae results in a 
transient infection. Cpn antigen peaked at the one-month time point followed by a peak in 
beta amyloid at the two-month time point. Amyloid deposits reduced as Cpn antigen 
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burden reduced over time (44) . This is in contrast with the in vivo passaged isolate, which 
resulted in a progressive pathology over time (40) . These results suggest that the in vivo 
passaged isolate of Cpn is more virulent than the stock isolate of Cpn. 
For both isolates, the trend follows that when there are fewer glial cells, amyloid 
is more abundant. Additionally, as glial cell counts increased, there is less amyloid 
deposited. This finding is supported by previous research, which supports that glial cells 
phagocytose beta amyloid, resulting in activation and an increase in glial cell number and 
a reduction ofbeta amyloid (46-48, 50). 
The in vivo passaged C small Weiss isolate of C. muridarum displayed a positive 
trend when comparing chlamydia antigen to glial cell counts. As glial cell count 
increased, the amount of C. muridarum antigen also increased. However, for the stock 
isolate of C. muridarum, mouse pneumonitis Weiss, as glial cell count increased, the 
amount of C. muridarum antigen decreased. This fuliher supports the hypothesis that the 
in vivo passaged isolate of C. muridarwn is more virulent than the stock isolate. While 
testing the vimlence of the two strains, Ramsey et al detennined that mice inoculated 
with the in vivo passaged isolate of C. muridarum were likely to establish a secondary 
infection regardless if the stock isolate or the in vivo passaged isolate caused the primary 
infection (49). Additionally, seroconversion rates were higher with low dose infections of 
both the urogenital and the respiratory tract with the in vivo passaged isolate when 
compared to the stock isolate. This indicates that the in vivo passaged isolate is better able 
to establish infection (49). This suppmis the hypothesis that the in vivo passaged C small 
Weiss is better able to establish an infection when introduced intranasally into BALB/c 
mice and, due to the high virulence of the organism, it is difficult for the glial cells to 
clear it fi:om the CNS. 
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Selective vulnerability in regions that are typically implicated in AD was not 
observed in GFAP specific labeling in either the C small Weiss (Figure 3) or the mouse 
pneumonitis Weiss group (Figure 4). However, this would not be atypical as the 60-day 
time point is relatively early to see an increase in astrocyte specific GF AP labeling in 
these areas. Studies using transgenic mouse models indicate an increase in activated 
astrocytes; however, enhancement of GF AP-positive astrocyte labeling is not seen at this 
early time point (51). A study by Mastrangelo et al utilized triple transgenic mice and 
observed GF AP-positive astrocyte labeling at nine months of age in the entorhinal cmiex, 
but did not observe robust labeling until the 18-month and 26-month time points (52). 
In summary, the cunent mouse model comparing glial cell activation and AD-like 
pathology indicates a virulence difference between the two isolates of C. muridarum. 
There is a greater chlamydia antigen burden and amyloid deposit burden in the titer 
positive C small Weiss group relative to the titer positive mouse pneumonitis Weiss 
group. The greatest documented difference with respect to burden was observed for 
amyloid between the two C. muridarum isolates, with MoPn displaying a four fold 
increase relative to titer negative mice and CSW displaying a 15-fold increase. A study 
by Rank: et al (20 12) measured the virulence oftwo isolates of C. trachoma tis in the 
conjunctiva of guinea pigs. They demonstrated that the attenuated AZ2 variant was 
slower growing and unable to elicit a strong inflammatory response compared to the 
"wild-type" SP6 isolate. This was due to a defect of AZ2 making it unable to activate the 
TLR2 receptor in the inflammatory pathway (53). In a similar study by Yeruva et al 
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studying the ability of the chlamydia! variants to ascend the genital tract, IL-8 levels were 
lower in secretions of AZ2 infected animals than SP6 infected animals. AZ2 was also not 
able to ascend the genital tract to the oviduct as readily as SP6, which may be related to 
the inability of AZ2 to elicit a strong inflammatory response (54). This is consistent with 
the cmTent hypothesis that, in general, the in vivo passaged isolates of C. muridarum are 
more virulent. Thus, CSW induced greater AD-like pathology than MoPn. 
The amount of glial cell burden observed in this study was isolate specific. The 
initial hypothesis proposed that glial cell burden would increase in response to chlamydia 
infection and amyloid pathology. For CSW, as chlamydia antigen burden increased, glial 
cell counts also increased. The relationship of glial cells and chlamydia antigen burden 
differed from the initial hypothesis for MoPn. As chlamydia antigen burden increased, 
glial cell counts decreased. The relationship of glial cells and amyloid burden also 
differed from the initial hypothesis. There was inverse conelation between glial cell 
count and amyloid deposit burden in the CSW group. There is a considerably greater 
inverse conelation between glial cell count and amyloid deposit burden in the MoPn 
group than that observed in the CSW group. Therefore, the relationship of glial cells with 
amyloid and chlamydia antigen is isolate specific. 
5. Future Directions 
This study sought to detennine if AD-like pathology and chlamydia infection led 
to an increase in activated astrocytes in the brains ofBALB/c mice. It was hypothesized 
that as chlamydia antigen burden and amyloid deposit burden increased, the amount of 
activated glia would also increase. This trend was seen in only the C small Weiss isolate 
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of C. muridarum comparing glial cell count to chlamydia antigen burden. As chlamydia 
antigen burden increased, the amount of activated glial cells decreased. As chlamydia 
antigen burden increased in the mouse pneumonitis Weiss group, the amount of activated 
glial cells also increased . For both groups, there was an inverse conelation between 
amyloid burden and glial cell count. However, the presence of outliers in the small 
sample size demonstrates the need for a larger number of animals. In addition it would be 
beneficial to analyze glial cell activation at additional time points, including the 30-day 
time point, 90-day time point, and 120-day time point. This would allow us to dete1mine 
whether the strains we are working .with are inducing a chronic infection with progressive 
pathology or a transient infection with transient pathology, both of which have been 
observed in BALB/c mice infected with C. pneumoniae (40, 44). By increasing the 
sample size and looking at different time points, a more conclusive conelation between 
intranasal infection with C. muridarum, development of AD-like pathology, and 
inflammation in mouse brain tissue can be established. 
To determine if the in vivo passaged isolate of C. muridarum is more virulent that 
the stock isolate, the use of cell culture would be beneficial. If the in vivo passaged isolate 
of C. muridarum is, in fact, more virulent, it is hypothesized that it will replicate faster. 
Previous studies observed that the main difference in virulence between two isolates of 
chlamydia conelated with replication rate or "burst size" (49, 55). Higher replication 
rates conespond to a greater ability to establish infection in the host, and therefore a 
greater potentially damaging inflammatory response. A greater sample size with analysis 
at various time points combined with cell culture of C. muridarum will provide more 
evidence that this organism can produce AD-like pathology and inflammation in the 
brains ofBALB/c mice. 
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